Sustainability | November 01, 2024
Lupin to develop inhalers with near-zero global warming potential propellants
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Granules now has a total of 67 ANDA approvals from the USFDA
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Subscribe To Our Newsletter & Stay Updated
